Innovative therapies for rare diseases
The acquisition will help to drive the growth of CTI’s lead product, kinase inhibitor VONJO® (pacritinib) "in treating myeloproliferative disease,” stated Dr
"There is a large unmet medical need within myelofibrosis, in particular for patients suffering from thrombocytopenia who are inadequately treated by existing medicines. The combination [of CTI's team], together with Sobi's broad US and global haematology capabilities, will help get this much needed new therapy to patients faster and more effectively," commented
The biopharma companies anticipate the transaction will help to change the treatment landscape for patients with rare diseases through new, innovative and effective medicines and therapies.
Advancing haematology treatments
According to
Approved by the
Closing of the tender offer will be subject to certain conditions. The transaction is expected to close in the third quarter of 2023.
The post
© Russell Publishing Limited, 2023. All Rights Reserved., source